How We Treat Primary Hyperoxaluria Type 1
Clin J Am Soc Nephrol
.
2024 Jun 1;19(6):800-802.
doi: 10.2215/CJN.0000000000000460.
Epub 2024 Mar 18.
Authors
Matthew C Breeggemann
1
,
Peter C Harris
2
,
John C Lieske
2
3
,
Gregory E Tasian
4
5
,
Kyle D Wood
6
Affiliations
1
Division of Nephrology, University of California San Francisco, San Francisco, California.
2
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
3
Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota.
4
Division of Urology, Department of Surgery, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
5
Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania.
6
Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama.
PMID:
38494457
DOI:
10.2215/CJN.0000000000000460
No abstract available
MeSH terms
Humans
Hyperoxaluria, Primary* / complications
Hyperoxaluria, Primary* / diagnosis
Hyperoxaluria, Primary* / therapy
Treatment Outcome
Supplementary concepts
Primary hyperoxaluria type 1
Grants and funding
Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company